Skip to main content

Top Stories

Based on the findings of a budget analysis for third-party US payer plans, treatment with selinexor for patients with penta-refractory multiple myeloma had a small and manageable impact.

According to a Cedars-Sinai study, robotic surgery for patients with early-stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival.

News

News

A misconduct scandal at the University of Kentucky has led to the demotion of a senior cancer researcher for his lack of oversight of a now-former scientist who fabricated data in at least four papers and two grant applications.

The FDA has announced a new approved indication for olaparib (Lynparza) in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The US FDA has granted accelerated approval to pomalidomide (Pomalyst, Bristol-Myers Squibb) for the treatment of AIDS-related Kaposi sarcoma that is resistant to highly active antiretroviral therapy (HAART) or that occurs in HIV-negative

FDA Approvals

FDA Approvals

The FDA is set to approve biosimilar products through a new regulatory pathway that will help foster competition between biologics.

The FDA granted accelerated approval to belantamab mafodotin-blmf for the treatment of adults with relapsed or refractory MM previously given at least 4 therapies (eg, an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulato

The FDA has approved ripretinib tablets for the treatment of advanced gastrointestinal stromal tumor, or GIST, in the fourth-line setting.

Breast Cancer

Breast Cancer

This randomized phase 3 clinical trial evaluates the effect of a carboplatin-plus-paclitaxel regimen on survival, compared with a standard-dose regimen of cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel, in women with operable

Breast cancer patients who use certain supplements before and during chemotherapy are more likely to experience disease recurrence and related death than those who do not use supplements.

CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?

Adjuvant endocrine therapy, in the form of oral antiestrogens (tamoxifen and aromatase inhibitors) alone or in combination with ovarian function suppression for many younger women, reduces the risk of recurrence and saves lives.

Journal of Clinical Oncology
09/23/2020

Clinical Trials

Clinical Trials

A restrictive blood transfusion strategy in myocardial infarction patients with anemia proved safe, significantly less costly, and at least as effective as the standard liberal transfusion strategy.

The phase III CALGB 90203/Alliance trial has shown no improvement in 3-year biochemical progression-free survival with the addition of neoadjuvant chemohormonal therapy to radical prostatectomy in patients with localized high-risk prostate cancer.

Data from a phase Ib trial showed that treatment with RO7198457, a personalized cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab was well-tolerated and clinically beneficial among patients with advanced solid tumors.

Colorectal Cancer

Colorectal Cancer

The 2-stage pull-through hand-sewn coloanal anastomosis is safe for use in patients with low rectal cancer who have undergone resection, with a similar complication rate to standard treatment.

Interventions focused on social determinants of health to improve breast, cervical, and colorectal cancer screening appear to be cost-effective for underserved, vulnerable populations in the United States, according to results...

Patients with colorectal cancer (CRC) who have peritoneal metastases should only be treated in a specialized referral center and given systemic chemotherapy...

Gastrointestinal Cancer

Gastrointestinal Cancer

Providing an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment.

The National Comprehensive Cancer Network (NCCN) published updated guidelines for the treatment of gastric and esophageal and esophagogastric junction cancers.

U.S. FDA approved ripretinib (Qinlock™) for adult patients with advanced gastrointestinal stromal tumors (GISTs) who received prior treatment with three or more kinase inhibitors, including imatinib.

Spotlight

For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete.

Research & Outcomes

Research & Outcomes

Upcoming news in research funding; Aethlon, UPMC land $3.5M NIDCR grant...

Investigators recently launched the CHASING COVID Cohort study to help physicians and policymakers understand the impact of our public health response to the pandemic on clinical outcomes, and to prepare for future health crises.

Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a recent stu

Gynecologic Cancer

Gynecologic Cancer

Researchers found that a restrictive prescribing practice allows for a substantial reduction in the quantity of opioids prescribed, while patients remained highly satisfied with their pain management.

The Society of Gynecologic Oncology (SGO) has published guidelines for care during the COVID-19 pandemic crisis, recommending that clinicians engage patients in shared decision making about anticancer treatment, including considering potential ris

A new study found that half of younger uterine and ovarian cancer survivors are at a higher risk for osteoporosis, according to findings released by the Society of Gynecologic Oncology (Abstract 130).

Payment & Policy

Payment & Policy

Stephen M Schleicher, MD, MBA, explains how the Oncology Care Model could better foster the use of appropriate cancer therapies as well as how clinical pathways might be a solution.

Journal of Clinical Pathways spoke with Debra Patt, MD, MPH, MBA, vice president of policy strategy, Texas Oncology, on how regular coverage policy updates by commercial payers complicates the reimbursement of telemedicine services.

In June 2019, the Community Oncology Alliance (COA) announced a detailed alternative payment model (APM) that includes proposals for value-based contracts that would provide high-quality oncology care at a low cost. 

First-Year OCM Participation Associated With Fewer Visits, Lower Costs

Findings from a recent study showed that in the first year, cancer centers that implement payment models with shared-savings components can be associated with fewer visits and lower costs, however these savings are largely offset by the cost of program administration.

Journal of Clinical Pathways
08/22/2020

CMMI Announces OCM Adjustments During the Pandemic

The Center for Medicare and Medicaid Innovation (CMMI) announced new flexibilities to the OCM during COVID-19, including adjustments to payment methodology, quality reporting, and the overall timeline of the model.

Journal of Clinical Pathways
07/29/2020

Lung Cancer

Lung Cancer

The FDA has accepted and given priority review to AstraZeneca‘s application requesting a new dosing regimen for Imfinzi (durvalumab) to treat certain non-small cell lung cancer (NSCLC) and bladder cancer patients.

A history of pneumonitis increases the risk that patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy...

A new test, the first to combine liquid biopsy and next generation sequencing has been approved by the US FDA for use in patients with metastatic nonsmall cell lung cancer...